Biosensors for Alzheimer's disease biomarker detection: A review

Shui, Bingqing; Tao, Dan; Florea, Anca; Cheng, Jing; Zhao, Qianqian; Gu, Yingying; Li, Wen; Jaffrézic‐Renault, Nicole; Mei, Yong; Guo, Zhenzhong

doi:10.1016/j.biochi.2017.12.015

Cited by 113 publications

(61 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AD is a multifactorial disease that evolves progressively until the first symptoms of dementia appear with variable clinical among patients. This fluidity difficulties detection only by cognitive tests, favoring misdiagnosis and delaying medication administration [ 8 ]. Due to that, biomarkers have gained importance for an early diagnosis of AD.…”

Section: Biomarkers For Alzheimer’s Diseasementioning

confidence: 99%

“…The diagnose of AD can be performed by conducting cognitive tests and by imaging techniques, mainly magnetic resonance imaging (MRI), positron emission tomography (PET) and near infrared (NIR), used to detect abnormalities in patient brains [ 7 ]. The analysis of cerebrospinal fluid (CSF) and blood plasma biomarkers by immunohistochemistry and enzyme linked immunosorbent assay (ELISA) have also been used [ 8 ]. These techniques are time-consuming, expensive and invasive and do not constitute a generalize method for an early detection of AD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

Toyos-Rodríguez

Alonso

Escosura‐Muñiz

2020

Sensors

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is an untreatable neurodegenerative disease that initially manifests as difficulty to remember recent events and gradually progresses to cognitive impairment. The incidence of AD is growing yearly as life expectancy increases, thus early detection is essential to ensure a better quality of life for diagnosed patients. To reach that purpose, electrochemical biosensing has emerged as a cost-effective alternative to traditional diagnostic techniques, due to its high sensitivity and selectivity. Of special relevance is the incorporation of nanomaterials in biosensors, as they contribute to enhance electron transfer while promoting the immobilization of biological recognition elements. Moreover, nanomaterials have also been employed as labels, due to their unique electroactive and electrocatalytic properties. The aim of this review is to add value in the advances achieved in the detection of AD biomarkers, the strategies followed for the incorporation of nanomaterials and its effect in biosensors performance.

show abstract

Section: Biomarkers For Alzheimer’s Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

Toyos-Rodríguez

Alonso

Escosura‐Muñiz

2020

Sensors

View full text Add to dashboard Cite

show abstract

“…Magnetic resonance imaging (MRI) and positron emission tomography (PET) are the diagnostic methods used to predict the stage of AD pathology in clinical practice [ 3 , 4 , 5 , 6 ]. However, PET has poor spatial resolution and artifacts of movements, and MRI has low scanning velocity and motion artifacts [ 7 ]. Furthermore, these are costly and can have disagreeable activations such as queasiness, megrim, vomiting, fulminate and itching.…”

Section: Introductionmentioning

confidence: 99%

A Probeless Capacitive Biosensor for Direct Detection of Amyloid Beta 1-42 in Human Serum Based on an Interdigitated Chain-Shaped Electrode

Park

Cho

2020

Micromachines

View full text Add to dashboard Cite

Amyloid beta (aβ) 1-42, a peptide that is 1-42 amino acids long, is a major component of senile plaques in the brains of patients with Alzheimer’s disease. Aβ detection has become an essential antecedence to predict the declining mental abilities of patients. In this paper, a probeless capacitive biosensor for the non-Faradaic detection of aβ 1-42 peptide was developed by immobilizing a specific anti-aβ antibody onto a self-assembled monolayer functionalized interdigitated chain-shaped electrode (anti-aβ/SAM/ICE). The novelty and difference of this article from previous studies is the direct detection of aβ peptide with no redox probe ((Fe(CN)6)3−/4−), which can avoid the denaturation of the protein caused by the metallization (binding of aβ to metal ion Fe which is presented in the redox couple). The direct detection of aβ with no redox probe is performed by non-Faradaic capacitive measurement, which is greatly different from the Faradaic measurement of the charge transfer resistance of the redox probe. The detection of various aβ 1-42 peptide concentrations in human serum (HS) was performed by measuring the relative change in electrode interfacial capacitance due to the specific antibody-aβ binding. Capacitance change in the anti-aβ/SAM/ICE biosensor showed a linear detection range between 10 pg mL−1 and 104 pg mL−1, and a detection limit of 7.5 pg mL−1 in HS, which was much lower than the limit of detection for CSF aβ 1-42 (~500 pg mL−1) and other biosensors. The small dissociation constant Kd of the antibody-antigen interaction was also found to be 0.016 nM in HS, indicating the high binding affinity of the anti-aβ/SAM/ICE biosensor in the recognizing of aβ 1-42. Thus, the developed sensor can be used for label-free and direct measurement of aβ 1-42 peptide and for point-of-care diagnosis of Alzheimer’s disease without redox probe.

show abstract

“…We do not accept the idea that the existence of a prevalence in one or the other sex legitimizes the view that there is a biological origin that explains ASD. We suggest that there are other possible interpretations of this prevalence that include both the gender bias in the diagnosis and the gender bias in the research studies, but developing this suggestion is beyond the scope of this paper.22 Although there are currently no biomarkers that can be used in the clinic to predict Alzheimer's and Parkinson's diseases before neuronal deterioration begins to appear, a great advance has been made in finding proteins and specific candidate genes associated with this deterioration(Redensek et al, 2018;Shui et al, 2017).…”

mentioning

confidence: 99%

Natural kinds, normative kinds and human behavior

Pérez

Ciccia²

2019

Filosofia Unisinos

View full text Add to dashboard Cite

The main thesis of this paper is that a large part of human behavior cannot be understood in terms of natural kinds but by appealing to normative kinds. In the first section we explain the distinction between natural kinds and normative kinds. In the second section we focus on the notion of "human behavior", proposing a distinction between type A and type B behaviors and pointing out that psychology deals with type B behaviors, which are also included as diagnostic criteria for mental disorders. In the third section we analyze the strategies used in biomedical research to find specific etiologies ("essences") in order to explain such disorders. We argue that their results are inconsistent and that the lack of biomarkers that are clinically useful to refine the diagnoses is due to the fact that, unlike certain neuropathologies, there are no physiological essences behind such disorders. On the other hand, we argue that, as we are dealing with type B behaviors, we must interpret mental disorders as normative kinds.

show abstract

Biosensors for Alzheimer's disease biomarker detection: A review

Cited by 113 publications

References 84 publications

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

A Probeless Capacitive Biosensor for Direct Detection of Amyloid Beta 1-42 in Human Serum Based on an Interdigitated Chain-Shaped Electrode

Natural kinds, normative kinds and human behavior

Contact Info

Product

Resources

About